Articles tagged "Kidney transplantation"

2020 American Transplant Congress
Tissue Resident Memory T Cells in Mouse Renal Transplantation
K. Abou-Daya¹, D. Zhao¹, R. Tieu¹, R. Rammal², M. Oberbarnscheidt¹, F. Lakkis¹
¹Starzl Transplantation Institute, Pittsburgh, PA, ²American University of Beirut, Beirut, Lebanon
*Purpose: The newly identified tissue resident subset of memory T cells (TRM) provides immune surveillance in the tissue and first response against infections. They are…
2020 American Transplant Congress
Development of a New Kidney Paired Donation (KPD) Program: Starting a Domino Chain with a Deceased Donor
L. Furian¹, C. Di Bella², C. Silvestre², F. Neri², F. Tuci², M. Cardillo³, E. Cozzi⁴, P. Rigotti¹
¹Kidney and Pancreas Transplantation Unit, University of Padova, Padua, Italy, ²Kidney and Pancreas Transplantation Unit, University of Padova, Italy, Italy, ³Italian National Transplant Center, Rome, Rome, Italy, ⁴Transplant Immunology Unit, Padova University-Hospital, Padua, Padua, Italy
*Purpose: The option of initiating a domino chain of living donor kidney transplants with a deceased donor (DD) has been proposed but never enforced. The…
2020 American Transplant Congress
Three Year Post Co-Stimulation Blocking Agent (Belatacept) Switch Outcomes of Kidney Transplant Patients Diagnosed with Post-Transplant Thrombotic Microangiopathy
A. Gamilla-Crudo, S. Hussain, A. Rizvi, R. Ramirez, M. Kueht, H. Stevenson-Lerner, J. Fair, M. Mujtaba
UTMB, Galveston, TX
*Purpose: Thrombotic microangiopathy (TMA) can happen after kidney transplant. It may occur de novo or as a recurrent disease. De novo is usually associated with…
2020 American Transplant Congress
The Clinical Significance of C1q+ Antibodies in Pediatric Kidney Transplant Recipients
N. Hayde¹, S. Solomon², A. Colovai¹
¹Montefiore Medical Center, Bronx, NY, ²Westchester Medical Center, Valhalla, NY
*Purpose: To evaluate the impact of denovo DSA (C1q+ vs C1q-) on graft outcomes in pediatric kidney transplant recipients.*Methods: Children transplanted between 2009 and 2016…
2020 American Transplant Congress
Uromodulin to Osteopontin Ratio in Deceased Donor Urine is Associated with Kidney Graft Outcomes
S. G. Mansour¹, C. Liu², Y. Jia², P. Reese³, I. Hall⁴, T. El-Achkar⁵, K. LaFavers⁵, W. Obeid², M. Thangamani⁶, A. Rosenberg², M. Doshi⁷, E. Akalin⁸, J. Bromberg⁹, M. Harhay¹⁰, S. Mohan¹¹, B. Schröppel¹², P. Daneshpajouhnejad², P. Singh¹³, F. Weng¹⁴, H. Thiessen-Philbrook², C. Parikh²
¹Yale, New Haven, CT, ²Johns Hopkins, Baltimore, MD, ³UPenn, Philadelphia, PA, ⁴Univ of Utah, Salt Lake City, UT, ⁵Indiana Univ, Bloomington, IN, ⁶Cornell, New York, NY, ⁷Univ of Michigan, Ann Arbor, MI, ⁸Montefiore, Bronx, NY, ⁹Univ of Maryland, College Park, MD, ¹⁰Drexel, Philadelphia, PA, ¹¹Columbia, NY, NY, ¹²Univ Hosp, Ulm, Germany, ¹³Thomas Jefferson, Philadelphia, PA, ¹⁴St. Barnabas, Livingston, NJ
*Purpose: Deceased-donor kidneys often experience extensive injury, activating adaptive and maladaptive pathways. While these adaptive and maladaptive mechanisms are initiated in donor kidneys prior to…
2020 American Transplant Congress
Your Path to Transplant Tailored Education Increases Living Donation Transplant Actions and Wait-Listing Rates: Final Randomized Controlled Trial Findings
A. Waterman¹, Y. Cui², J. L. Beaumont², J. D. Peipert³, A. Paiva⁴, M. L. Robbins⁴
¹Transplant Research and Education Center, Los Angeles, CA, ²Terasaki Research Institute, Los Angeles, CA, ³Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Department of Psychology, University of Rhode Island, Kingston, RI
*Purpose: Tailoring education and behavior change interventions to address gaps in individual patients’ knowledge, readiness, and socio-economic challenges may help more end-stage kidney disease patients…
2020 American Transplant Congress
Multi-Center, Open-Label Trial of Pre-Emptive Glecaprevir/Pibrentasvir (G/P) to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus (MYTHIC)
M. Sise¹, D. Goldberg², J. Kort³, D. Schaubel⁴, R. Alloway⁵, C. Durand⁶, R. Fontana⁷, J. Friedewald⁸, R. Brown⁹, S. Prenner¹⁰, R. Landis⁴, P. Reese¹¹, R. Chung¹
¹Internal Medicine - Nephrology, MGH, Boston, MA, ²Hepatology and Transplantation, U Miami, Miami, FL, ³Abbvie, Chicago, IL, ⁴Department of Biostatistics, U Penn, Philadelphia, PA, ⁵Department of Internal Medicine - Nephrology and Hypertension, U Cincinnati, Cincinnati, OH, ⁶Department of Medicine, JHU, Baltimore, MD, ⁷Internal Medicine - Gastroenterology, U Michigan, Ann Arbor, MI, ⁸Internal Medicine - Nephrology and Hypertension, Northwestern, Chicago, IL, ⁹Internal Medicine - Hepatology, Weill Cornell, NYC, NY, ¹⁰Internal Medicine - Gastroenterology, U Penn, Philadelphia, PA, ¹¹Transplant Nephrology, U Penn, Philadelphia, PA
*Purpose: Kidneys from Hepatitis C virus (HCV)-infected deceased donors continue to be discarded at high rates despite small, successful studies of HCV-viremic donors into uninfected…
2020 American Transplant Congress
Feasibility and Long Term Safety of T Regulatory Cell Therapy in Kidney Transplantation
P. N. Harden¹, D. Game², J. Van der Net¹, F. Issa³, W. Petchey¹, M. Brook¹, P. Friend¹, R. Hilton⁴, G. Lombardi⁵, K. Wood³
¹Kidney Transplantation, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ²Kidney Transplantation, Guys and St Thomas's Hospital, London, United Kingdom, ³Transplant Immunology Research Group, Oxford University, Oxford, United Kingdom, ⁴Kidney Transplantation, Guys and St Thomas's Hospital, Oxford, United Kingdom, ⁵Transplant Immunology Group, Kings Healthcare Partners, London, United Kingdom
*Purpose: A sequential clinical trial of autologous polyclonal T regulatory cellular therapy compared with a standardised reference cohort of live donor kidney transplant recipients. The…
2020 American Transplant Congress
The Impact Of Weight Reduction Surgery And Morbid Obesity On Renal Function After Transplantation
S. Negi¹, N. Saberi¹, P. Bouchard², a. Andalib², M. Cantarovich¹, S. Paraskevas¹, J. Tchervenkov¹
¹RIMUHC, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada
*Purpose: Morbid obesity is a significant barrier and renal transplantation is rarely offered to patients with Class III obesity (body mass index (BMI) > 40…
2020 American Transplant Congress
Benefits of Transplantation Over Chronic Dialysis in Septugenerian ESRD Patients with Diabetes
S. Karhadkar, A. Shaik, A. Di Carlo
Temple University School of Medicine, Philadelphia, PA
*Purpose: In 2016, nearly 125,000 adults in the United States began treatment for end-stage renal disease (ESRD) (i.e., kidney failure requiring dialysis or transplantation). Of…